Literature DB >> 2987659

Kinetics of binding of membrane-active drugs to receptor sites. Diffusion-limited rates for a membrane bilayer approach of 1,4-dihydropyridine calcium channel antagonists to their active site.

D G Rhodes, J G Sarmiento, L G Herbette.   

Abstract

Using the model of 1,4-dihydropyridine calcium channel-blocking drug binding to receptors in the cardiac sarcolemmal membrane, diffusion-limited rates of association were calculated for two distinct approaches. In the "aqueous approach," the drug reaches the receptor by diffusion through the bulk solvent, whereas in the "membrane approach," the drug partitions into the membrane bilayer and then diffuses laterally to a specific receptor site. Calculated rates for the membrane approach were approximately 3 orders of magnitude greater than those for the aqueous approach. The membrane approach diffusion-limited rate depends weakly on the sizes of the binding site, the drug molecule, and the vesicle, but depends strongly on ligand asymmetry. Although the measured binding rates for several 1,4-dihydropyridines were all slower than the calculated diffusion-limited rates for either model, other experimental data (such as very high partition coefficients and specific positions of these drugs in the membrane bilayer) suggest that the membrane approach is the most likely. These results have important implications for specifying critical characteristics of active 1,4-dihydropyridines.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2987659

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  36 in total

1.  Solid-state NMR and MD simulations of the antiviral drug amantadine solubilized in DMPC bilayers.

Authors:  Conggang Li; Myunggi Yi; Jun Hu; Huan-Xiang Zhou; Timothy A Cross
Journal:  Biophys J       Date:  2007-09-21       Impact factor: 4.033

2.  Structural analysis of drug molecules in biological membranes.

Authors:  L G Herbette; D W Chester; D G Rhodes
Journal:  Biophys J       Date:  1986-01       Impact factor: 4.033

3.  Mathematical modelling and computational study of two-dimensional and three-dimensional dynamics of receptor-ligand interactions in signalling response mechanisms.

Authors:  Pilar García-Peñarrubia; Juan J Gálvez; Jesús Gálvez
Journal:  J Math Biol       Date:  2013-07-28       Impact factor: 2.259

4.  Omega-conotoxin: direct and persistent blockade of specific types of calcium channels in neurons but not muscle.

Authors:  E W McCleskey; A P Fox; D H Feldman; L J Cruz; B M Olivera; R W Tsien; D Yoshikami
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

Review 5.  Drugs and receptors. An overview of the current state of knowledge.

Authors:  T Kenakin
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

6.  Interaction of the NMDA receptor noncompetitive antagonist MK-801 with model and native membranes.

Authors:  J Moring; L A Niego; L M Ganley; M W Trumbore; L G Herbette
Journal:  Biophys J       Date:  1994-12       Impact factor: 4.033

7.  Does the Lipid Bilayer Orchestrate Access and Binding of Ligands to Transmembrane Orthosteric/Allosteric Sites of G Protein-Coupled Receptors?

Authors:  Christopher T Szlenk; Jeevan B Gc; Senthil Natesan
Journal:  Mol Pharmacol       Date:  2019-04-08       Impact factor: 4.436

8.  Diffusion of dihydropyridine calcium channel antagonists in cardiac sarcolemmal lipid multibilayers.

Authors:  D W Chester; L G Herbette; R P Mason; A F Joslyn; D J Triggle; D E Koppel
Journal:  Biophys J       Date:  1987-12       Impact factor: 4.033

9.  Radioligand and functional estimates of the interaction of the 1,4-dihydropyridines, isradipine and lacidipine, with calcium channels in smooth muscle.

Authors:  S Salomone; T Godfraind
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

10.  Novel halogenated dihydropyridine derivatives with high vascular selectivity.

Authors:  U Fricke; W Klaus; B Stein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-10       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.